The standard practice of a 6-8 cycle chemotherapy induction followed by maintenance wasn't a deliberate trial design. It evolved organically from patient intolerance to cumulative toxicities like neuropathy, a limitation newer, less toxic drugs like TDXD don't necessarily share.

As patients with metastatic gastroesophageal cancer live longer, managing long-term toxicity like neuropathy is crucial. Experts recommend stopping oxaliplatin after just 6-8 cycles. By month six, if disease is controlled, some even stop 5-FU, continuing only with the biologic agent to improve quality of life.

Beyond managing hyperglycemia, GLP-1 inhibitors have been observed to improve neuropathy in diabetic patients receiving Enfortumab Vedotin (EV). This suggests a dual benefit, challenging the assumption that EV is the sole cause of worsening neuropathy in this population.

The neuropathy caused by polatuzumab vedotin can be severe and is not always reversible. Clinicians must be vigilant in assessing for symptoms like numbness or difficulty with fine motor skills and be prepared to reduce the dose promptly to prevent long-term, debilitating side effects.

For patients over 75 with metastatic gastric cancer, a common practice is to reduce the oxaliplatin dose from 85 to 65 mg/m² and universally omit the 5-FU bolus from the FOLFOX regimen. This pragmatic approach aims to maintain efficacy while minimizing toxicity in a more vulnerable population.

Clinicians emphasize that maintaining treatment continuity with a reduced, tolerable chemotherapy dose is superior to discontinuing therapy due to side effects. This approach helps patients stay on treatment longer, potentially improving overall survival.

While severe (Grade 3+) neuropathy from enfortumab vedotin is rare, oncologists emphasize that Grade 2 toxicity is common and significantly impairs patients' quality of life. This 'moderate' side effect is often painful and interferes with daily activities, warranting an immediate hold on treatment, not just waiting for Grade 3.

As a practical standard of care for elderly patients, one clinician universally avoids the 5-FU bolus in metastatic settings and reduces the oxaliplatin dose in the FOLFOX regimen from 85 mg/m² to 65 mg/m² for most patients over age 75. This adjustment balances efficacy with improved tolerability in a more vulnerable population.

With colorectal cancer rates rising in young adults, the long-term toxicity of oxaliplatin-induced peripheral neuropathy is a graver concern. A 30-year-old patient could face debilitating side effects for 40-50 years, fundamentally altering the risk-benefit calculation for adjuvant therapy.